IMMUNITYBIO INC (IBRX) Stock Analyst Ratings
NASDAQ:IBRX - Nasdaq - US45256X1037 - Common Stock - Currency: USD
ChartMill assigns a Buy % Consensus number of 84% to IBRX. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 12.43. This target is 263.49% above the current price.
IBRX was analyzed by 10 analysts. The buy percentage consensus is at 84. So analysts seem to be very confident about IBRX.
In the previous month the buy percentage consensus was at a similar level.
IBRX was analyzed by 10 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-02-19 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-02-14 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-01-30 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-01-27 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-01-16 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-01-10 | BTIG | Initiate | Buy |
| 2025-01-06 | D. Boral Capital | Maintains | Buy -> Buy |
| 2024-12-20 | D. Boral Capital | Maintains | Buy -> Buy |
| 2024-11-21 | D. Boral Capital | Maintains | Buy -> Buy |
| 2024-11-19 | D. Boral Capital | Maintains | Buy -> Buy |
| 2024-11-12 | D. Boral Capital | Maintains | Buy -> Buy |
| 2024-10-23 | EF Hutton | Initiate | Buy |
| 2024-08-19 | Piper Sandler | Maintains | Neutral -> Neutral |
| 2024-04-29 | Piper Sandler | Maintains | Neutral -> Neutral |
| 2024-03-25 | Piper Sandler | Maintains | Neutral -> Neutral |
| 2023-05-12 | Piper Sandler | Downgrade | Overweight -> Neutral |
| 2022-08-03 | Jefferies | Initiate | Buy |